Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 19/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 12/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23383994 | 1.00 | LPAR1 (0.41) | LPAR1LPAR3BRAF | |
| SCHEMBL25824396 | 0.94 | LPAR1 (0.41) | LPAR1LPAR3BRAF | |
| SCHEMBL25824493 | 0.94 | LPAR1 (0.45) | LPAR1LPAR3 | |
| SCHEMBL23383939 | 0.94 | LPAR1 (0.45) | LPAR1LPAR3 | |
| SCHEMBL23384031 | 0.92 | LPAR1 (0.41) | LPAR1LPAR3 | |
| SCHEMBL30482779 | 0.92 | LPAR1 (0.41) | LPAR1LPAR3 | |
| SCHEMBL23383995 | 0.89 | LPAR1 (0.41) | LPAR1LPAR3 | |
| SCHEMBL30073407 | 0.88 | LPAR1 (0.44) | LPAR1LPAR3 | |
| SCHEMBL23384394 | 0.88 | LPAR1 (0.44) | LPAR1LPAR3 | |
| SCHEMBL23384044 | 0.88 | LPAR1 (0.40) | LPAR1LPAR3BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4058144-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885BRAF 2096/4885 |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885BRAF 2096/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885BRAF 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.